Deodhar A, Gladman DD, McInnes IB, et al. - In this study, the immunogenicity of secukinumab was analyzed in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) exposed to secukinumab for up to 52 weeks. Using antibody bridging assays, the immunogenicity of secukinumab in patients with PsA [FUTURE 1–3 studies, and AS (MEASURE 1–4 studies)] were tested. Researchers characterized treatment-emergent antidrug antibodies (TE-ADA) as a positive ADA signal in ≥ 1 posttreatment sample in patients negative at baseline. They evaluated positive samples for drug-neutralizing potential, and impact of TE-ADA on secukinumab pharmacokinetics, immunogenicity-related adverse events, and efficacy through Week 52 were analyzed. Of 1414 treated PsA and 1164 treated AS individuals with samples available for immunogenicity assessment, 5 (0.35%) and 8 (0.69%), respectively, established TE-ADA. Among patients with PsA or AS, results reveal that secukinumab treatment was correlated with a low (< 1%) incidence of immunogenicity.